Epilepsy

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is sleep disorders.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 6, 2023.

Using treatment failures and antiseizure medication retention, findings pointed to levetiracetam as a more effective initial monotherapy in females with juvenile myoclonic epilepsy.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is epilepsy and seizure disorders.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 29, 2023.

The associate professor of neurology at NYU Grossman School of Medicine discussed her talk at IFN 2023 on advancements in epilepsy treatments, highlighting new medications and surgical options. [WATCH TIME: 3 minutes]

The codirector of the Mount Sinai Epilepsy Program at the Icahn School of Medicine at Mount Sinai talked about the Women in Neurology and Leadership session she spoke in at IFN 2023. [WATCH TIME: 3 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is headache and migraine.

In the largest meta-analysis of patients with poststroke seizures, findings showed that those with early seizures had a greater mortality risk than those with late.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 22, 2023.

The director of the Pediatric Epilepsy Center at UCSF provided perspective on the advances in the treatment of Dravet syndrome, emerging research concepts in the field, and the influence of genetic testing. [WATCH TIME: 5 minutes]

The director of the Pediatric Epilepsy Center at UCSF discussed STK-001, an antisense oligonucleotide in development for Dravet syndrome, and the promise behind this type of targeted approach. [WATCH TIME: 4 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Alzheimer and dementia.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 15, 2023.

The director of the Pediatric Epilepsy Center at UCSF provided perspective on STK-001, a promising antisense oligonucleotide in development, and the shift in how Dravet syndrome is discussed and managed.

Patients treated for more than 28 days had a higher chance of status epilepticus cessation, but also a high risk of moderate to severe disability at discharge.

One meta-analysis featuring 8 studies showed that more than half of patients reported a 100% reduction in their generalized tonic-clonic seizures or tonic-clonic seizures.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is stroke.

Researchers developed a novel “closed-loop” system that delivered electrical pulses in a brain region to synchronize brain activity recorded from another region in the brain to improve memory.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 8, 2023.